{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:48:44Z","timestamp":1769507324562,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,13]]},"DOI":"10.7759\/cureus.43429","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T17:46:26Z","timestamp":1691948786000},"source":"Crossref","is-referenced-by-count":1,"title":["Simultaneous Thoracic Spine Metastatic Melanoma and Pre-existing Prostate Adenocarcinoma: A Unique Case Presentation and Literature Review"],"prefix":"10.7759","author":[{"given":"Srikanth  A","family":"Venkata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narek","family":"Hakobyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akriti","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fares","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avezbakiyev","family":"Boris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Metastatic melanoma","author":"Sundararajan S","year":"2022","unstructured":"Sundararajan S, Thida A, Yadlapati S, Koya S. Metastatic melanoma. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092320","article-title":"Molecular markers and targets in melanoma","volume":"10","author":"Teixido C","year":"2021","unstructured":"Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular markers and targets in melanoma. Cells. 2021, 10:2320. 10.3390\/cells10092320","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238984","article-title":"Overcoming immune evasion in melanoma","volume":"21","author":"Eddy K","year":"2020","unstructured":"Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020, 21:8984. 10.3390\/ijms21238984","journal-title":"Int J Mol Sci"},{"key":"ref4","unstructured":"Melanoma skin cancer statistics. (2023). Accessed. January 12, 2023: https:\/\/www.cancer.org\/cancer\/types\/melanoma-skin-cancer\/about\/key-statistics.html."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000466","article-title":"Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome","volume":"28","author":"G\u00f3mez-Le\u00f3n N","year":"2018","unstructured":"G\u00f3mez-Le\u00f3n N, Pacheco-Barcia V, Ballesteros AI, Fraga J, Colomer R, Friera A. Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. Melanoma Res. 2018, 28:562-70. 10.1097\/CMR.0000000000000466","journal-title":"Melanoma Res"},{"key":"ref6","unstructured":"Mayo Foundation for Medical Education and Research. Prostate cancer. (2022). Accessed. July 10, 2023: https:\/\/www.mayoclinic.org\/diseases-conditions\/prostate-cancer\/symptoms-causes\/syc-20353087."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014107","article-title":"Malignant melanoma with indiscoverable skin manifestations presenting with paresis and refractory hypercalcemia: a case report","volume":"98","author":"Wang PP","year":"2019","unstructured":"Wang PP, Zhou X, Chen X, Wang LW, Liu Y. Malignant melanoma with indiscoverable skin manifestations presenting with paresis and refractory hypercalcemia: a case report. Medicine (Baltimore). 2019, 98:e14107. 10.1097\/MD.0000000000014107","journal-title":"Medicine (Baltimore)"},{"key":"ref8","article-title":"Lumbosacral radiculopathy secondary to L5 metastatic melanoma of unknown primary","volume":"77","author":"Ku A","year":"1996","unstructured":"Ku A, Henry A, Tunkel R, Lachmann E, Nagler W. Lumbosacral radiculopathy secondary to L5 metastatic melanoma of unknown primary. Arch Phys Med Rehabil. 1996, 77:307-9.","journal-title":"Arch Phys Med Rehabil"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis LE","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019, 20:1366-79. 10.1080\/15384047.2019.1640032","journal-title":"Cancer Biol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf L","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, et al.. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000, 31:578-83. 10.1053\/hp.2000.6698","journal-title":"Hum Pathol"},{"key":"ref11","unstructured":"Mayo Foundation for Medical Education and Research. Prostate cancer. (2022). Accessed. July 10, 2023: https:\/\/www.mayoclinic.org\/diseases-conditions\/prostate-cancer\/diagnosis-treatment\/drc-20353093."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7020670","article-title":"A possible association between melanoma and prostate cancer. Results from a case-control-study","volume":"7","author":"Goldenberg A","year":"2015","unstructured":"Goldenberg A, Jiang SI, Cohen PR. A possible association between melanoma and prostate cancer. Results from a case-control-study. Cancers (Basel). 2015, 7:670-8. 10.3390\/cancers7020670","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a024244","article-title":"The role of steroid hormones in prostate carcinogenesis","volume":"27","author":"Bosland MC","year":"2000","unstructured":"Bosland MC. The role of steroid hormones in prostate carcinogenesis. JNCI Monogr. 2000, 27:39-66. 10.1093\/oxfordjournals.jncimonographs.a024244","journal-title":"JNCI Monogr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16203915","article-title":"Skin melanoma and subsequent risk of prostate cancer: a Lithuanian cancer registry study","volume":"16","author":"Patasius A","year":"2019","unstructured":"Patasius A, Urbonas V, Smailyte G. Skin melanoma and subsequent risk of prostate cancer: a Lithuanian cancer registry study. Int J Environ Res Public Health. 2019, 16:3915. 10.3390\/ijerph16203915","journal-title":"Int J Environ Res Public Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2174\/157340608783789185","article-title":"Photoperiod and testosterone modulate growth and melanogenesis of s91 murine melanoma","volume":"4","author":"Allil PA","year":"2008","unstructured":"Allil PA, Visconti MA, Castrucci AM, Isoldi MC. Photoperiod and testosterone modulate growth and melanogenesis of s91 murine melanoma. Med Chem. 2008, 4:100-5. 10.2174\/157340608783789185","journal-title":"Med Chem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1915","article-title":"Personal history of prostate cancer and increased risk of incident melanoma in the United States","volume":"31","author":"Li WQ","year":"2013","unstructured":"Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, Han J. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol. 2013, 31:4394-9. 10.1200\/JCO.2013.51.1915","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-4804(03)00005-2","article-title":"Androgen blockade enhances response to melanoma vaccine","volume":"110","author":"Hsueh E","year":"2003","unstructured":"Hsueh E, Gupta R, Lefor A, Reyzin G, Ye W, Morton D. Androgen blockade enhances response to melanoma vaccine. J Surg Res. 2003, 110:393-8. 10.1016\/s0022-4804(03)00005-2","journal-title":"J Surg Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23032","article-title":"Acne and risk of prostate cancer","volume":"121","author":"Sutcliffe S","year":"2007","unstructured":"Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. Int J Cancer. 2007, 121:2688-92. 10.1002\/ijc.23032","journal-title":"Int J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02027-7","article-title":"Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and up study","volume":"128","author":"Egger S","year":"2023","unstructured":"Egger S, Smith D, Patel M, Kimlin M, Armstrong B, Nair-Shalliker V. Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and up study. Br J Cancer. 2023, 128:71-9. 10.1038\/s41416-022-02027-7","journal-title":"Br J Cancer"},{"key":"ref20","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","author":"Stahl JM","year":"2003","unstructured":"Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003, 63:2881-90.","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604680","article-title":"Is PTEN loss associated with clinical outcome measures in human prostate cancer?","volume":"99","author":"McCall P","year":"2008","unstructured":"McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer?. Br J Cancer. 2008, 99:1296-301. 10.1038\/sj.bjc.6604680","journal-title":"Br J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.248","article-title":"Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer","volume":"108","author":"Cuzick J","year":"2013","unstructured":"Cuzick J, Yang ZH, Fisher G, et al.. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer. 2013, 108:2582-9. 10.1038\/bjc.2013.248","journal-title":"Br J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00430-4","article-title":"Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer","volume":"25","author":"Velez MG","year":"2022","unstructured":"Velez MG, Kosiorek HE, Egan JB, et al.. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022, 25:479-83. 10.1038\/s41391-021-00430-4","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu H","year":"2003","unstructured":"Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003, 22:3113-22. 10.1038\/sj.onc.1206451","journal-title":"Oncogene"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3037","article-title":"PTEN loss in the continuum of common cancers, rare syndromes and mouse models","volume":"11","author":"Hollander MC","year":"2011","unstructured":"Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011, 11:289-301. 10.1038\/nrc3037","journal-title":"Nat Rev Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4342","article-title":"Screening for skin cancer: US preventive services task force recommendation statement","volume":"329","author":"Mangione CM","year":"2023","unstructured":"Mangione CM, Barry MJ, Nicholson WK, et al.. Screening for skin cancer: US preventive services task force recommendation statement. JAMA. 2023, 329:1290-5. 10.1001\/jama.2023.4342","journal-title":"JAMA"},{"key":"ref27","article-title":"Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Evidence-Based Best Practice Guidelines","author":"National Health and Medical Research Council","year":"2008","unstructured":"National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Evidence-Based Best Practice Guidelines. New Zealand Guidelines Group, Wellington; 2008."},{"key":"ref28","unstructured":"Canadian Cancer Society. Skin exam. (2023). Accessed. June 17, 2023: https:\/\/cancer.ca\/en\/treatments\/tests-and-procedures\/skin-exam."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.18","article-title":"Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening","volume":"146","author":"Bigby M","year":"2010","unstructured":"Bigby M. Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening. Arch Dermatol. 2010, 146:322-4. 10.1001\/archdermatol.2010.18","journal-title":"Arch Dermatol"},{"key":"ref30","unstructured":"Screening for melanoma in adults and adolescents. (2023). Accessed. April 24, 2023: https:\/\/www.uptodate.com\/contents\/screening-for-melanoma-in-adults-and-adolescents."},{"key":"ref31","unstructured":"Cancer Council. Clinical practice guidelines and resources. (2023). Accessed. February 2, 2023: https:\/\/www.cancer.org.au\/health-professionals\/clinical-practice-guidelines."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29408","article-title":"The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era","volume":"137","author":"Jahn JL","year":"2015","unstructured":"Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Cancer. 2015, 137:2795-802. 10.1002\/ijc.29408","journal-title":"Int J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic D","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, et al.. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018, 362:k3519. 10.1136\/bmj.k3519","journal-title":"BMJ"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9083-8","article-title":"Quantifying the role of PSA screening in the US prostate cancer mortality decline","volume":"19","author":"Etzioni R","year":"2008","unstructured":"Etzioni R, Tsodikov A, Mariotto A, et al.. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008, 19:175-81. 10.1007\/s10552-007-9083-8","journal-title":"Cancer Causes Control"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.05.068","article-title":"Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"62","author":"Schr\u00f6der FH","year":"2012","unstructured":"Schr\u00f6der FH, Hugosson J, Carlsson S, et al.. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012, 62:745-52. 10.1016\/j.eururo.2012.05.068","journal-title":"Eur Urol"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der F","year":"2014","unstructured":"Schr\u00f6der F, Hugosson J, Roobol M, et al.. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014, 384:2027-35.","journal-title":"Lancet"},{"key":"ref37","unstructured":"Screening for prostate cancer. (2023). Accessed. June 8, 2023: https:\/\/www.uptodate.com\/contents\/screening-for-prostate-cancer."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"Pinsky PF","year":"2017","unstructured":"Pinsky PF, Prorok PC, Yu K, et al.. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017, 123:592-9. 10.1002\/cncr.30474","journal-title":"Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1207165","article-title":"Quality of life and guidelines for PSA screening","volume":"367","author":"Sox HC","year":"2012","unstructured":"Sox HC. Quality of life and guidelines for PSA screening. N Engl J Med. 2012, 367:669-71. 10.1056\/NEJMe1207165","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.644885","article-title":"Variation in the use of active surveillance for low-risk prostate cancer across US census regions","volume":"11","author":"Al Hussein Al Awamlh B","year":"2021","unstructured":"Al Hussein Al Awamlh B, Patel N, Ma X, Calaway A, Ponsky L, Hu JC, Shoag JE. Variation in the use of active surveillance for low-risk prostate cancer across US census regions. Front Oncol. 2021, 11:644885. 10.3389\/fonc.2021.644885","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/171702-simultaneous-thoracic-spine-metastatic-melanoma-and-pre-existing-prostate-adenocarcinoma-a-unique-case-presentation-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:57Z","timestamp":1707508917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/171702-simultaneous-thoracic-spine-metastatic-melanoma-and-pre-existing-prostate-adenocarcinoma-a-unique-case-presentation-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.43429","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,13]]}}}